Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Study Of The Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis

Next Previous
Search
Trial Profile

A Multicenter, Open-Label Study Of The Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational
  • Sponsors Anacor Pharmaceuticals; Pfizer

    • Most Recent Events

    • 17 Aug 2017 Results assessing long term safety, published in the Journal of the American Academy of Dermatology.
    • 17 May 2016 Results presented at the IMMUNOLOGY 2016 American Association of Immunologists Annual Meeting
    • 22 Mar 2016 According to an Anacor Pharmaceuticals media release, the US FDA has accepted for review New Drug Application (NDA) seeking approval of crisaborole topical ointment 2% for the treatment of mild-to-moderate atopic dermatitis in children and adults with PDUFA date of January 7, 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top